D-1167-2017 Class II Terminated

Recalled by Pfizer Inc. — New York, NY

FDA drug recall D-1167-2017 was initiated by Pfizer Inc. on Aug 22, 2017 and is designated Class II. Reason for recall: Lack of sterility assurance: resulting from use of a damaged sterilizing filter for nitrogen used in the manufacturing process. The recall status is terminated (terminated Feb 19, 2023). Affected quantity: 115,370 vials.

Recall details

Product Type
Drugs
Report Date
Sep 27, 2017
Initiation Date
Aug 22, 2017
Termination Date
Feb 19, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
115,370 vials

Product description

HYDROmorphone HCl Injection, USP, 2 mg/mL, 1mL Single-use vial, packaged in cartons of 25 vials, Rx only, Hospira, Inc., Lake Forest, IL 60045 USA, NDC 0409-3365-11 (carton) and 0409-3365-01(vial)

Reason for recall

Lack of sterility assurance: resulting from use of a damaged sterilizing filter for nitrogen used in the manufacturing process.

Distribution pattern

United States Nationwide (including Puerto Rico) and Singapore

Code information

Lot: 760853A

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1167-2017
openFDA file date
Nov 19, 2026
Loaded by RegDataLab
Nov 20, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Need the full FDA record for Pfizer Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: openFDA record for D-1167-2017. Report a data issue: hello@regdatalab.com.